GlassScriptPhysician profile
Erin N Smith
NPI 1447373337
$4,144.81
in general payments reported to CMS, 2019-2025
32 companies · $945 in 2025
The $945 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $634 · 2023: $716 · 2024: $1,615 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.01 |
| Travel and Lodging | $427.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.32 | 2022-2025 | |
| Arthrex, INC. | $471.35 | 2024 | |
| Lilly USA, LLC | $457.52 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $386.15 | 2023-2025 | |
| Stryker Corporation | $184.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $183.00 | 2024-2025 | Airsupra, Breztri |
| Heron Therapeutics, INC. | $181.77 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $167.52 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $137.82 | 2024 | Watchman Flx |
| Verrica Pharmaceuticals INC. | $104.31 | 2024 | Ycanth |
| Neurocrine Biosciences, INC. | $78.09 | 2022 | |
| Novo Nordisk INC | $77.20 | 2024 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $71.77 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $64.14 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $58.05 | 2023-2024 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.11 | 2022-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.94 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $50.53 | 2022-2025 | Dificid, Gardasil 9, Enflonsia |
| W. L. Gore & Associates, INC. | $45.53 | 2024-2025 | Gore Synecor Biomaterial |
| Bayer Healthcare Pharmaceuticals INC. | $43.82 | 2023 | |
| Corium, LLC | $41.67 | 2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $39.96 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.32 | 2022 | |
| Seqirus USA INC | $32.01 | 2022-2025 | Flucelvax |
| Novartis Pharmaceuticals Corporation | $29.88 | 2022 | |
| Pacira Therapeutics, INC. | $29.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.52 | 2022-2023 | Quviviq |
| Aimmune Therapeutics, INC. | $24.62 | 2025 | Vowst |
| Eisai INC. | $22.57 | 2024 | |
| Neos Therapeutics, LP | $19.13 | 2022 | |
| Lundbeck LLC | $16.63 | 2025 | Rexulti |
| Heraeus Medical, LLC. | $14.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.